Latest GenomeDx Biosciences Stories
Data from Multiple Studies Include Potential Ability for Technology to Further Subtype Patients, Guide Treatment Decisions SAN DIEGO, Feb.
Multiple Studies of Decipher Prostate Cancer Classifier Presented at 2015 ASCO Genitourinary Symposium SAN DIEGO, Feb.
Decipher is the first genomic test for postoperative prostate cancer to gain Medicare coverage SAN DIEGO, Jan.
First study to show that the genomic signature of prostate cancer can predict rapid development of metastatic disease in men who were managed conservatively after surgery SAN DIEGO, Dec.
Builds on initial collaboration with Mayo Clinic that led to the development and commercialization of Decipher in patients following prostate surgery SAN DIEGO, Nov.
SAN DIEGO, Oct.
SAN DIEGO, Sept. 25, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement with MultiPlan, Inc. for diagnostic laboratory testing.
Oral presentation at American Society for Radiation Oncology Annual Meeting describes Decipher's ability to identify high-risk prostate cancer patients that may benefit from radiation therapy after
Data presented at American Society for Radiology (ASTRO) Annual Meeting in San Francisco SAN FRANCISCO, Sept.
SAN DIEGO, June 16, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement as a participating provider with Prime Health Services to provide
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.